January 30 – February 1, 2023 | San Francisco, CA
The 3rd TGF-β for Immuno-Oncology Drug Development Summit is your one-stop-shop dedicated to harnessing you with the knowledge to unlock the potential of successfully targeting TGF-β.
From uncovering the effects and production of TGF-β in immune, tumor and stromal cells to exploring predictive and pharmacodynamic TGF-β biomarkers for patient identification and assessing the clinical challenges that led to recent clinical failures.
Tailored with 18+ senior leaders, including a presentation illuminating the TGF-β for Immuno-Oncology landscape from Beacon’s own Research Analyst, Aysha Saeed, the 2023 meeting will be taking place in-person for the first time – don’t miss your chance to be in the room for your comprehensive guide on TGF-β in immuno-oncology!
Whether you are new to this field or a seasoned expert, this meeting will provide you with the must-know takeaways from the basic biology to biomarkers to clinical trial design to overcome the clinical setbacks and produce a blockbuster TGF-β therapeutic.